ReviewMediators of inflammation2010
Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages.
Review in Mediators of inflammation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 100 citations in OpenAlex.
- Adipocyte Enhancer Binding Protein 1 (AEBP1) Inhibition as a Potential Anti-Fibrotic Therapy in Heart Failure.Research square · 2026Article
- FAM-related prognostic molecular subtype screening identified epithelial-derivedFrontiers in cell and developmental biology · 2026Article
- Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms.Current Alzheimer research · 2026Review
- Targeting Adipocyte Enhancer-Binding Protein 1 to Induce Microglial Phenotype Shift for Immunotherapy in Alzheimer's Disease.International journal of molecular sciences · 2025Article
- Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- AEBP1 inhibition reduces cell growth and PI3K/AKT pathway while less regulates cell mobility in hepatocellular carcinoma.World journal of surgical oncology · 2025Article
- A novel Wnt/β-catenin signaling gene signature for progression and metastasis of gastric cancer.Oncology research · 2025Article
- Article
- Dysregulated AEBP1 and COLEC12 Genes in Late-Onset Alzheimer's Disease: Insights from Brain Cortex and Peripheral Blood Analysis.Journal of molecular neuroscience : MN · 2024Article
- Review
- Anti-Inflammatory Effect ofMolecules (Basel, Switzerland) · 2024Article
- Utilize proteomic analysis to identify potential therapeutic targets for combating sepsis and sepsis-related death.Frontiers in endocrinology · 2024Article
- Therapeutic and Phytochemical Properties of Thymoquinone Derived fromCurrent drug research reviews · 2024Review
- SUMOylation targeting mitophagy in cardiovascular diseases.Journal of molecular medicine (Berlin, Germany) · 2022Review
- SOD3 Suppresses the Expression of MMP-1 and Increases the Integrity of Extracellular Matrix in Fibroblasts.Antioxidants (Basel, Switzerland) · 2022Article
- Screening prognostic genes related to leucovorin, fluorouracil, and irinotecan treatment sensitivity by performing co-expression network analysis for colon cancer.Frontiers in genetics · 2022Article
- Mechanistic interplay of various mediators involved in mediating the neuroprotective effect of daphnetin.Pharmacological reports : PR · 2021Review
- Anti-Inflammatory Effects of 6-Methylcoumarin in LPS-Stimulated RAW 264.7 Macrophages via Regulation of MAPK and NF-κB Signaling Pathways.Molecules (Basel, Switzerland) · 2021Article
- Immunomodulatory Effects of Green Tea Polyphenols.Molecules (Basel, Switzerland) · 2021Review
- Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons.ACS omega · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NF-kappaB comprises a family of transcription factors that are critically involved in various inflammatory processes. In this paper, the role of NF-kappaB in inflammation and atherosclerosis and the regulation of the NF-kappaB signaling pathway are summarized. The structure, function, and regulation of the NF-kappaB inhibitors, IkappaBalpha and IkappaBbeta, are reviewed. The regulation of NF-kappaB activity by glucocorticoid receptor (GR) signaling and IkappaBalpha sumoylation is also discussed. This paper focuses on the recently reported regulatory function that adipocyte enhancer-binding protein 1 (AEBP1) exerts on NF-kappaB transcriptional activity in macrophages, in which AEBP1 manifests itself as a potent modulator of NF-kappaB via physical interaction with IkappaBalpha and a critical mediator of inflammation. Finally, we summarize the regulatory roles that recently identified IkappaBalpha-interacting proteins play in NF-kappaB signaling. Based on its proinflammatory roles in macrophages, AEBP1 is anticipated to serve as a therapeutic target towards the treatment of various inflammatory conditions and disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.